Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

Oct 12, 2018

|

NEW YORK (GenomeWeb) – New data this week has added evidence for the value of blood-based cancer testing in non-small cell lung cancer, demonstrating in a cohort of about 300 that comprehensive liquid biopsy — in this case Guardant Health's Guardant360 test — can help identify targeted mutations in more patients than tissue sequencing.

The study also found that patients treated on the basis of blood-based test results respond to treatment similarly to those treated based on tissue test results.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Possible Effect of Border DNA Testing

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

Commission to Develop Report on Germline Editing

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

To Boost Productivity

The US Department of Agriculture presents a new blueprint for animal genomic research.

This Week in Genome Research

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.

Featured White Papers

BlueBee Data Security & Compliance

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Type 1 Interferon Gene Expression Analysis: Precision Medicine in Lupus

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Jun

18

Featured Webinar

Clinical Genomics of NTRK Fusion Detection in Cancer

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect.

Jun

19

Featured Webinar

Genome-Wide NIPT for Rare Chromosomal Conditions: Technical, Biological, and Clinical Considerations

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jun

25

Featured Webinar

Menu